Affinage

IL10RA

Interleukin-10 receptor subunit alpha · UniProt Q13651

Length
578 aa
Mass
63.0 kDa
Annotated
2026-04-28
78 papers in source corpus 15 papers cited in narrative 15 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IL-10RA is the ligand-binding alpha chain of the interleukin-10 receptor that transduces anti-inflammatory and immunomodulatory signals through JAK1/TYK2-dependent STAT3 phosphorylation, with additional engagement of AKT-mTOR signaling in certain cell contexts. Two cytoplasmic tyrosine residues (Tyr446 and Tyr496) are essential for recruitment and activation of the downstream effector IL-10E1 and for productive STAT3 signaling (PMID:12802285), while surface IL-10RA abundance is dynamically regulated—upregulated by type I/III interferons to sensitize monocytes/macrophages to IL-10 (PMID:22685028), transcriptionally repressed by BCL6 to restrain an IL-10RA/JAK2/STAT3 survival circuit in B-cell lymphoma (PMID:27268052), and modulated at an enhancer by NF-κB1 binding (PMID:39844988). Loss-of-function mutations—including missense variants that prevent plasma-membrane localization (p.Tyr91Cys) and synonymous variants that cause exon skipping (p.T179T)—abolish IL-10-induced STAT3 activation and underlie very-early-onset inflammatory bowel disease (PMID:30462267, PMID:27177777). Conversely, aberrant IL-10RA upregulation in anaplastic large cell lymphoma provides a bypass route for STAT3 phosphorylation that confers resistance to ALK inhibitors (PMID:32573700).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2003 High

    Identification of the cytoplasmic signaling residues of IL-10RA resolved how the receptor couples ligand binding to downstream effector activation: Tyr446 and Tyr496 are necessary and sufficient for IL-10E1 recruitment and phosphorylation.

    Evidence Phosphopeptide co-precipitation, site-directed Tyr→Ser mutagenesis, and GFP-fusion confocal imaging in human cell lines

    PMID:12802285

    Open questions at the time
    • Structural basis of selectivity between Tyr446 and Tyr496 for different STAT family members not resolved
    • No kinase reconstitution mapping which JAK isoform phosphorylates each tyrosine
  2. 2006 Low

    Demonstration that proximal JAK1/TYK2–STAT1/STAT3 signaling downstream of IL-10RA is intact in SLE PBMCs established that disease-associated dysregulation occurs at the transcriptional output level rather than at receptor-proximal kinase activation.

    Evidence Phospho-Western blot for JAK1, TYK2, STAT1, STAT3 and cDNA array in SLE patient PBMCs

    PMID:17062437

    Open questions at the time
    • Single lab with descriptive gene-expression profiling; no mechanistic dissection of downstream transcriptional deviation
    • Small patient cohort limits generalizability
  3. 2012 Medium

    Type I and type III interferons were shown to upregulate surface IL-10RA on monocytes/macrophages, establishing a feed-forward mechanism by which antiviral interferons amplify IL-10 anti-inflammatory signaling through enhanced STAT3 phosphorylation.

    Evidence Flow cytometry for IL-10RA surface expression, phospho-STAT3 Western blot, and IL-12p70 ELISA in IFN-primed primary human monocytes/macrophages

    PMID:22685028

    Open questions at the time
    • Transcription factor(s) mediating IFN-induced IL10RA upregulation not identified
    • Whether IFN-driven IL-10RA upregulation occurs in vivo during infection not tested
  4. 2016 Medium

    Three concurrent studies established that loss-of-function IL10RA mutations cause very-early-onset IBD through distinct molecular mechanisms—exon skipping from a synonymous variant (p.T179T) and protein misfolding/mislocalization from a missense variant (p.Tyr91Cys)—both converging on abolished STAT3 activation.

    Evidence RT-PCR for exon skipping, STAT3 phosphorylation assays in patient PBMCs, flow cytometry and confocal microscopy for membrane localization, structural modeling

    PMID:26822028 PMID:27177777 PMID:30462267

    Open questions at the time
    • Rescue experiments (e.g., wild-type IL10RA transduction restoring STAT3 signaling) not reported for all variants
    • Whether these variants affect receptor complex formation with IL-10RB specifically not tested
  5. 2016 High

    BCL6 was identified as a direct transcriptional repressor of the IL-10RA/JAK2 axis, revealing that de-repression of IL-10RA surface expression activates a JAK2/STAT3 survival pathway in Burkitt lymphoma.

    Evidence ChIP-seq and in vitro ChIP for BCL6 binding at JAK2 promoter, conditional BCL6-deficient cell line, anti-IL-10RA antibody blockade abolishing STAT3 phosphorylation, xenograft validation

    PMID:27268052

    Open questions at the time
    • Whether BCL6 binds the IL10RA promoter directly or acts solely through JAK2 regulation is not fully resolved
    • Generalizability to other B-cell lymphoma subtypes not established
  6. 2016 Medium

    IL-10RA was shown to inhibit autophagy through dual STAT3 and AKT-mTOR pathway activation, broadening IL-10RA signaling output beyond STAT3 alone.

    Evidence Pharmacological inhibitors of AKT, mTOR, and STAT3 each reversed IL-10-mediated autophagy suppression in primary hypertrophic scar fibroblasts; TEM for autophagosome quantification

    PMID:26962683

    Open questions at the time
    • Whether AKT-mTOR activation occurs directly from IL-10RA cytoplasmic domain or indirectly via STAT3 target genes not distinguished
    • Genetic validation (e.g., IL-10RA knockdown) not performed
  7. 2020 High

    Genome-wide CRISPR screens revealed that aberrant IL-10RA upregulation provides a STAT3 phosphorylation bypass route in ALCL, explaining ALK inhibitor resistance and directly linking IL-10RA expression level to therapeutic outcome.

    Evidence CRISPR activation and knockout screens in ALCL cell lines, RNA-seq from ALK inhibitor-relapsed patient tumors, STAT3 signaling assays

    PMID:32573700

    Open questions at the time
    • Therapeutic targeting of IL-10RA in resistant ALCL not yet tested
    • Whether IL-10RA upregulation is selected clonally or induced by the tumor microenvironment is unclear
  8. 2021 Medium

    ATG16L1 WD40 domain interaction with IL-10RB was shown to facilitate IL-10 receptor endocytosis and early trafficking, linking autophagy machinery to IL-10R signaling efficiency without affecting receptor degradation.

    Evidence Co-immunoprecipitation of ATG16L1 WDD with IL-10RB, endocytosis and trafficking assays after IL-10 stimulation

    PMID:34251955

    Open questions at the time
    • Direct physical or functional role of ATG16L1 on IL-10RA (vs. IL-10RB) not demonstrated
    • Mechanism by which WDD facilitates endocytosis (adaptor recruitment, clathrin involvement) not resolved
  9. 2024 Medium

    IL-10RA signaling in mesenchymal stem cells was shown to drive IDO expression through STAT3, establishing a mechanism by which stromal cells suppress anti-tumor T cell responses in the pancreatic cancer microenvironment.

    Evidence IL-10RA knockdown in human bone marrow MSCs, co-culture with T cells, IDO activity assay, PDAC organoid killing assay

    PMID:39592739

    Open questions at the time
    • Whether IL-10RA on MSCs is the dominant immunosuppressive receptor in vivo not established
    • Source of IL-10 in the tumor microenvironment driving this axis not identified
  10. 2024 Medium

    Enhancer-level regulation of IL10RA was mechanistically defined: the SNP rs4936415 C-allele recruits NF-κB1 to modulate enhancer activity and serum IL-10Rα levels, connecting genetic variation to receptor abundance.

    Evidence Luciferase reporter assay, EMSA and ChIP for NF-κB1 binding, ELISA for serum IL-10Rα in Behçet disease patients

    PMID:39844988

    Open questions at the time
    • Whether NF-κB1-mediated regulation affects surface IL-10RA on immune cells specifically not tested
    • Functional consequence of altered serum IL-10Rα on IL-10 signaling not established
  11. 2025 Medium

    Nonlinear, hysteretic IL-10R expression dynamics were demonstrated in tumor-infiltrating immune cells, showing that the tumor microenvironment locks immune cells into an IL-10Rhi state exploitable by intratumoral bacteria.

    Evidence Engineered Salmonella in multiple mouse tumor models, flow cytometry of IL-10R states, phagocytosis and T cell expansion assays, human tumor sample analysis

    PMID:40037354

    Open questions at the time
    • Molecular mechanism underlying hysteretic IL-10R expression (epigenetic, transcriptional feedback) not defined
    • IL-10RA vs. IL-10RB contribution to the hysteretic behavior not dissected

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis for how IL-10RA cytoplasmic domain differentially recruits JAK1 versus JAK2, and how receptor expression level quantitatively tunes the switch between immunosuppressive STAT3 signaling and oncogenic STAT3 bypass, remains mechanistically unresolved.
  • No high-resolution structure of full-length IL-10RA including the cytoplasmic domain
  • Quantitative threshold model for IL-10RA expression driving anti-inflammatory versus pro-tumoral STAT3 signaling not formalized
  • In vivo genetic rescue of IL10RA-deficient IBD models with defined mutants not reported

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 4 GO:0060090 molecular adaptor activity 2
Localization
GO:0005886 plasma membrane 2 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 6 R-HSA-1643685 Disease 4 R-HSA-168256 Immune System 3
Partners
ATG16L1BCL6IL10RBJAK1JAK2NFKB1STAT3TYK2
Complex memberships
IL-10 receptor complex (IL-10RA/IL-10RB)

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 Two specific tyrosine residues in the cytoplasmic domain of IL-10Rα (Tyr446 and Tyr496) are required for receptor function and for phosphorylation and activation of the downstream effector IL-10E1. Phosphorylated peptides encompassing these residues co-precipitate IL-10E1 and block ligand-dependent IL-10E1 phosphorylation, whereas peptides with serine substitutions at these positions do not prevent IL-10E1 activation. In vitro cell-free immunoprecipitation with phosphopeptides, site-directed mutagenesis (serine substitutions), confocal microscopy of GFP-fusion constructs, microinjection assays in human prostate cancer cell lines Oncogene High 12802285
2012 IFN-α priming upregulates IL-10R1 (IL-10RA) surface expression on human monocytes and macrophages, thereby increasing their sensitivity to IL-10 stimulation as measured by higher STAT3 phosphorylation, which in turn suppresses TLR-induced IL-12p70 production. IFN-β and IL-29 (type III IFN) produce a comparable effect, indicating a general IFN-class effect on IL-10RA-mediated signaling. Flow cytometry (IL-10R1 surface expression), Western blot (STAT3 phosphorylation), ELISA (IL-12p70), primary human monocyte/macrophage cultures with IFN priming European journal of immunology Medium 22685028
2016 BCL6 directly represses the IL10RA gene by binding to the JAK2 promoter and suppressing surface IL-10RA expression; BCL6 deficiency in Burkitt lymphoma cells elevates surface IL-10RA, increases JAK2 mRNA/protein, and activates STAT3 phosphorylation. Blockade of IL-10RA with an antibody represses STAT3 phosphorylation, defining an IL-10RA/JAK2/STAT3 survival pathway held in check by BCL6. Conditional BCL6-deficient cell line (DG75-AB7), synthetic lethal small-molecule screen, ChIP-seq (BCL6 binding at JAK2 promoter), in vitro ChIP, IL-10RA surface blockade with antibody, Western blot (STAT3 phosphorylation), xenograft in vivo studies The Journal of biological chemistry High 27268052
2016 IL-10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via IL-10Rα-mediated activation of both the STAT3 pathway and the AKT-mTOR pathway, converging at mTOR-p70S6K. Pharmacological blockade of IL-10Rα (using IL-10RB antagonist), p-AKT (LY294002), p-mTOR (rapamycin), or p-STAT3 (cryptotanshinone) each reversed IL-10-mediated autophagy inhibition. Transmission electron microscopy (autophagy), Western blot (p-AKT, p-STAT3, p-mTOR, p-p70S6K), pharmacological inhibitor dissection in primary hypertrophic scar fibroblasts, immunostaining and PCR for IL-10Rα expression Cell death & disease Medium 26962683
2016 The synonymous IL10RA variant p.T179T, located before the 5' splice donor site of exon 4, causes exon skipping and out-of-frame fusion of exons 3 and 5, resulting in a non-functional receptor and defective STAT3 phosphorylation in response to IL-10 stimulation in patient PBMCs. Splicing analysis (RT-PCR demonstrating exon skipping), functional assay (STAT3 phosphorylation in patient-derived PBMCs stimulated with IL-10), Sanger sequencing Journal of Crohn's & colitis Medium 27177777
2016 A novel exonic mutation in IL10RA (c.537G>A, p.T179T) causes unique splicing aberrations (exon skipping) resulting in loss of IL-10 receptor signaling, demonstrated by absent STAT3 phosphorylation in patient-derived cells stimulated with IL-10. Sanger sequencing, RT-PCR (splice aberration confirmation), functional IL-10 stimulation assay with STAT3 phosphorylation readout in patient PBMCs BMC gastroenterology Medium 26822028
2019 The IL-10RA missense variant p.Tyr91Cys causes structural instability by disrupting the hydrophobic core surrounding residue 91, resulting in failure of the mutant protein to properly localize to the plasma membrane and defective STAT3 activation in patient PBMCs upon IL-10 stimulation. Flow cytometry (plasma membrane localization of IL-10RA), confocal microscopy (GFP-fused mutant protein localization), STAT3 phosphorylation assay in patient PBMCs, computational structural analysis of IL-10RA protein Inflammatory bowel diseases Medium 30462267
2020 Aberrant upregulation of IL-10RA in anaplastic large cell lymphoma (ALCL) cells rewires STAT3 signaling by providing an alternative route of STAT3 phosphorylation that bypasses dependence on NPM1-ALK, thereby driving resistance to the ALK inhibitor crizotinib. This was demonstrated by genome-wide CRISPR activation and knockout screens combined with RNA-seq from relapsed patient tumors. Genome-wide CRISPR activation screen, CRISPR knockout screen in ALCL cell lines, RNA-seq from ALK inhibitor-relapsed patient tumors, functional STAT3 signaling assays Blood High 32573700
2021 ATG16L1, via its C-terminal WD40 domain (WDD), interacts with IL10RB (the beta chain of the IL-10 receptor complex) after IL-10 activation to facilitate endocytosis, early trafficking, and downstream signaling of IL-10/IL-10R complexes, without influencing the degradation rate of the receptor complex. Binding motif identification, Co-immunoprecipitation (ATG16L1 WDD with IL10RB), endocytosis and trafficking assays, IL-10 signaling functional assays, WDD domain mutagenesis (indirect, via T300A allele analysis in follow-up paper) Autophagy Medium 34251955
2024 In mesenchymal stem cells (MSCs), IL-10RA promotes IDO expression and T cell suppression through STAT3 phosphorylation. Knockdown of IL-10RA in MSCs significantly reduced IDO RNA and protein expression, decreased STAT3 phosphorylation, and inhibited IDO enzymatic activity, thereby relieving T cell suppression and restoring cytotoxicity against pancreatic cancer organoids. IL-10RA knockdown (siRNA/shRNA) in human bone marrow MSCs, co-culture with T cells, Western blot (IDO protein, p-STAT3), qRT-PCR (IDO RNA), IDO activity assay, PDAC organoid killing assay British journal of cancer Medium 39592739
2025 The hysteretic nonlinearity of IL-10R expression drives tumor-infiltrated immune cells into a tumor-specific IL-10Rhi state. Bacteria (engineered Salmonella) exploit this state to enhance tumor-associated macrophage IL-10 production and evade neutrophil phagocytosis, while coincidentally expanding exhausted tumor-resident CD8+ T cells through the same IL-10R-driven mechanism. Engineered Salmonella strain in multiple tumor mouse models, flow cytometry of IL-10R expression states, functional assays (phagocytosis, T cell expansion, tumor regression), analysis of human tumor samples Cell Medium 40037354
2006 In SLE patient PBMCs, IL-10 stimulation through IL-10R activates JAK1, TYK2, STAT1, and STAT3 at levels comparable to healthy controls, indicating intact proximal signaling; however, the downstream gene expression pattern induced through IL-10R is aberrant in SLE, particularly in genes involved in apoptosis, cytokines, and their receptors. Flow cytometry (IL-10R expression), Western blot (JAK1, TYK2, STAT1, STAT3 phosphorylation), cDNA array (242 genes) after IL-10 stimulation of patient PBMCs Scandinavian journal of rheumatology Low 17062437
2025 IL-10RA promotes proliferation and fatty acid oxidation (FAO) in non-small cell lung cancer cells via the STAT3 signaling pathway. Overexpression of IL-10RA enhanced glycolysis and FAO while increasing STAT3 activation, and a STAT3 inhibitor blocked IL-10RA-driven FAO and proliferation. IL-10RA overexpression and knockdown in NSCLC cell lines, Seahorse metabolic assays (glycolysis, FAO), STAT3 inhibitor (pharmacological), Western blot, bioinformatic pathway analysis Pulmonary pharmacology & therapeutics Low 39892560
2024 The IL10RA enhancer SNP rs4936415 regulates IL10RA transcription: the protective G-allele shows higher enhancer activity in luciferase reporter assays, while the risk C-allele specifically binds NF-κB1 (shown by EMSA and ChIP), which also increases enhancer activity; BD patients with risk alleles show lower serum IL-10Rα levels. Luciferase gene-reporter assay, chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), ELISA (serum IL-10Rα), post-GWAS bioinformatic analysis Heliyon Medium 39844988
2011 Promoter SNPs in IL10RA (rs56356146 and rs7925112) alter IL10RA gene expression as demonstrated by transient transfection assays, and specific combined haplotypes of IL10RA and IL10RB promoter variants are associated with protection against severe malaria. Transient transfection assays for allele-specific reporter expression, population-based haplotype analysis in malaria cohorts Immunogenetics Low 21814839

Source papers

Stage 0 corpus · 78 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflammatory bowel diseases 193 22550014
2000 Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 110 10939619
2013 A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood 109 24089328
2016 IL10 inhibits starvation-induced autophagy in hypertrophic scar fibroblasts via cross talk between the IL10-IL10R-STAT3 and IL10-AKT-mTOR pathways. Cell death & disease 68 26962683
2012 IL-10R blockade during chronic schistosomiasis mansoni results in the loss of B cells from the liver and the development of severe pulmonary disease. PLoS pathogens 53 22291593
2025 Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell 48 40037354
2007 Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver international : official journal of the International Association for the Study of the Liver 43 17845543
2022 The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review. Clinical and experimental immunology 39 35481870
2012 Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. European journal of immunology 36 22685028
2020 IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood 35 32573700
2016 Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease: a case report. BMC gastroenterology 35 26822028
2024 IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia 33 39215060
2015 Bone Marrow Mesenchymal Stromal Cells Induce Proliferative, Cytokinic and Molecular Changes During the T Cell Response: The Importance of the IL-10/CD210 Axis. Stem cell reviews and reports 33 25326368
2021 Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood cancer journal 31 34392305
2016 A Synonymous Variant in IL10RA Affects RNA Splicing in Paediatric Patients with Refractory Inflammatory Bowel Disease. Journal of Crohn's & colitis 30 27177777
2018 Umbilical Cord Blood Transplantation Corrects Very Early-Onset Inflammatory Bowel Disease in Chinese Patients With IL10RA-Associated Immune Deficiency. Inflammatory bowel diseases 29 29788474
2015 Association study of functional polymorphisms in interleukins and interleukin receptors genes: IL1A, IL1B, IL1RN, IL6, IL6R, IL10, IL10RA and TGFB1 in schizophrenia in Polish population. Schizophrenia research 29 26481614
2012 Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunology letters 28 23064239
2016 Early Diagnosis and Hematopoietic Stem Cell Transplantation for IL10R Deficiency Leading to Very Early-Onset Inflammatory Bowel Disease Are Essential in Familial Cases. Case reports in immunology 21 27699073
2010 Interleukin 10 receptor alpha subunit (IL-10RA) gene polymorphism and IL-10 serum levels in Egyptian atopic patients. Journal of investigational allergology & clinical immunology 21 20232770
2018 The expression of IL10RA in colorectal cancer and its correlation with the proliferation index and the clinical stage of the disease. Cytokine 19 29730384
2017 Expression of CD19+CD24highCD38high B cells, IL‑10 and IL‑10R in peripheral blood from patients with systemic lupus erythematosus. Molecular medicine reports 19 28901380
2013 Genetic evidence of regulatory gene variants of the STAT6, IL10R and FOXP3 locus as a susceptibility factor in uncomplicated malaria and parasitaemia in Congolese children. Malaria journal 19 23297791
2005 Polymorphism of the mouse gene for the interleukin 10 receptor alpha chain (Il10ra) and its association with the autoimmune phenotype. Immunogenetics 19 16160826
2013 TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10RA expression. Medical microbiology and immunology 18 23455702
2020 Intestinal dysbiosis in pediatric Crohn's disease patients with IL10RA mutations. World journal of gastroenterology 17 32587451
2018 Computational Protein Phenotype Characterization of IL10RA Mutations Causative to Early Onset Inflammatory Bowel Disease (IBD). Frontiers in genetics 14 29755507
2016 Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma. The Journal of biological chemistry 14 27268052
2011 Combined promoter haplotypes of the IL10R genes are associated with protection against severe malaria in Gabonese children. Immunogenetics 14 21814839
2019 Current concepts in pediatric inflammatory bowel disease; IL10/IL10R colitis as a model disease. International journal of pediatrics & adolescent medicine 13 31304220
2001 Semiautomated and simultaneous analysis of the interleukin-10 gene microsatellites IL-10G and IL-10R by fluorescence-based polymerase chain reaction reveals significant differences in allele distributions between Caucasians (Germany) and Africans (Gabon). European cytokine network 13 11566635
2023 Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma. Frontiers in immunology 12 37033926
2018 IL-10RA Mutation as a Risk Factor of Severe Influenza-Associated Encephalopathy: A Case Report. Pediatrics 11 29724880
2018 A strategy of targeting B10 cell by CD19scFv-IL10R for tumor therapy. Biochemical and biophysical research communications 11 30404730
2006 Expression and function of IL-10R in mononuclear cells from patients with systemic lupus erythematosus. Scandinavian journal of rheumatology 11 17062437
2024 A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells. Cellular oncology (Dordrecht, Netherlands) 10 39008193
1999 Polymorphisms within the interleukin-10 receptor cDNA gene (IL10R) in Japanese patients with systemic lupus erythematosus. Rheumatology (Oxford, England) 10 10556270
2025 Mechanistic insights curcumin's anti-inflammatory in pancreatic cancer: experimental and computational evidence implicating IL1B interference via IL10RA upregulation and NLRP3/TLR3 downregulation. Frontiers in cell and developmental biology 8 40535567
2023 Impact of Mycobacterium avium subsp. paratuberculosis infection on bovine IL10RA knockout mammary epithelial (MAC-T) cells. In vitro cellular & developmental biology. Animal 8 37071310
2020 Association of variants in IL1B, TLR9, TREM1, IL10RA, and CD3G and Native American ancestry on malaria susceptibility in Colombian populations. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 8 33316430
2003 IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines. Oncogene 8 12802285
2016 Genetic variant of IL-10RA and susceptibility to rheumatoid arthritis in a Chinese population. Clinical rheumatology 7 27796662
2021 Characterization of novel and large fragment deletions in exon 1 of the IL10RA gene in Chinese children with very early onset inflammatory bowel diseases. BMC gastroenterology 6 33849446
2017 Type I interferon signaling restrains IL-10R+ colonic macrophages and dendritic cells and leads to more severe Salmonella colitis. PloS one 6 29190678
2012 Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. American journal of hematology 6 22649007
2023 Association of IL10RA, IL10RB, and IL22RA Polymorphisms/Haplotypes with Susceptibility to and Clinical Manifestations of SLE. International journal of molecular sciences 5 37511050
2021 Establishment of human induced pluripotent stem cell line (SDQLCHi040-A) from a patient with Infantile-onset inflammatory bowel disease carrying a homozygous mutation in IL10RA gene. Stem cell research 5 34530396
2019 Novel Compound Heterozygote Mutation in IL10RA in a Patient With Very Early-Onset Inflammatory Bowel Disease. Inflammatory bowel diseases 5 30462267
2018 Compound heterozygous mutations in IL10RA combined with a complement factor properdin mutation in infantile-onset inflammatory bowel disease. European journal of gastroenterology & hepatology 5 30199474
2017 Determination of normal expression patterns of CD86, CD210a, CD261, CD262, CD264, CD358, and CD361 in peripheral blood and bone marrow cells by flow cytometry. Immunology letters 5 29274771
2016 Family-based association study of interleukin 10 (IL10) and interleukin 10 receptor alpha (IL10RA) functional polymorphisms in schizophrenia in Polish population. Journal of neuroimmunology 5 27397081
2024 IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity. British journal of cancer 4 39592739
2021 Case Report: A Novel Compound Heterozygous Mutation in IL-10RA in a Chinese Child With Very Early-Onset Inflammatory Bowel Disease. Frontiers in pediatrics 4 34113591
2019 Neonatal Crohn's disease with Oral ulcer as the first symptom caused by a compound heterozygote mutation in IL-10RA: a case report. Hereditas 4 31889944
2025 Successful Use of Anakinra in a Patient with IL-10R Beta Deficiency: A Case Report. Pediatric allergy, immunology, and pulmonology 3 39950990
2025 Treatment of IL-10RA deficiency of pediatric patients with very early onset inflammatory bowel disease by allogeneic haematopoietic stem cell transplantation. Scientific reports 3 40113867
2024 Successful Allogeneic Hematopoietic Cell Transplantation for Patients with IL10RA Deficiency in Japan. Journal of clinical immunology 3 39264505
2020 Fecal Microbial Signatures Are Associated With Engraftment Failure Following Umbilical Cord Blood Transplantation in Pediatric Crohn's Disease Patients With IL10RA Deficiency. Frontiers in pharmacology 3 33162889
2019 An integration-free iPSC line (SDQLCHi012-A) derived from a patient with inflammatory bowel disease- 28 carrying compound heterozygote mutations in IL10RA gene. Stem cell research 3 31648101
2025 IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway. Pulmonary pharmacology & therapeutics 2 39892560
2021 Unconventional WD40 domain-dependent role of ATG16L1 in the regulation of IL10R (interleukin 10 receptor) endocytosis, trafficking and signaling. Autophagy 2 34251955
2018 Association of IL-10 and IL-10RA single nucleotide polymorphisms with the responsiveness to HBV vaccination in Chinese infants of HBsAg(+)/HBeAg(-) mothers: a nested case-control study. BMJ open 2 30498038
2017 Data on IL-10R neutralization-induced chronic colitis in Lipocalin 2 deficient mice on BALB/c background. Data in brief 2 28349107
2025 Pitfalls in the diagnosis of apparent homozygous mutations: two cases of IL10RA deficiency inflammatory bowel disease and a literature review. Orphanet journal of rare diseases 1 40611267
2025 Lymphocytes and monocytes undergo swift suppression of IL-10R, IL-6R, and IL-2Rβγ signaling under high concentrations of different cytokines. bioRxiv : the preprint server for biology 1 40654786
2024 Characteristics of the gut microbiota and the effect of Bifidobacterium in very early-onset inflammatory bowel disease patients with IL10RA mutations. Frontiers in microbiology 1 39687875
2023 MiR-4763-3p accelerates lipopolysaccharide-induced cardiomyocyte apoptosis and inflammatory response by targeting IL10RA. Cytotechnology 1 38495290
2022 [Clinical characteristics and identification of a novel IL10RA variant in association with very early-onset inflammatory bowel disease]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 36082572
2019 Phenotypic characteristics and clinical manifestations of inflammatory bowel disease in infants and children under 2 years of age in Liaoning Province, China: five of six infants with IL-10R mutations. Paediatrics and international child health 1 30900524
2014 Content of IL-10 and CD4+CD210+ cells in mice with adjuvant arthritis before and after treatment with cryopreserved placental cells. Bulletin of experimental biology and medicine 1 25257438
2026 IL-10R inhibition induces neutrophil tumoricidal activity. Cancer immunology research 0 41499552
2026 Exploring genotype-phenotype correlations in three pediatric patients with IL10RA variants and very early-onset inflammatory bowel disease. BMC gastroenterology 0 41606474
2026 [Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation]. Zhongguo shi yan xue ye xue za zhi 0 41846353
2025 Identification of Novel IL-10RA Variant in Infantile-Onset Inflammatory Bowel Disease: A Case Series With Preliminary Genotype-Phenotype Correlation From Two Chinese Families. Case reports in medicine 0 41425514
2024 Correlation and Prediction of IL-10Ra and DKK-4 Plasma Levels in Patients with Calcium Oxalate Urolithiasis. Clinical laboratory 0 39506574
2024 Genetic predisposition to Behcet's disease mediated by a IL10RA enhancer polymorphism. Heliyon 0 39844988
2023 [Analysis of a child with Very early onset inflammatory bowel disease due to compound heterozygous variants of IL10RA and DUOX2 genes]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 0 37906150
2022 ATG16L1 WD40 domain-dependent IL10R (interleukin 10 receptor) signaling is insensitive to the T300A Crohn disease risk polymorphism. Autophagy 0 35311452